P3.02a-022 Experiences of Patients Receiving Treatment with Ceritinib to Treat ALK+ Non-Small Cell Lung Cancer: A Qualitative Study

Abstract

Conclusion:This study provides further evidence of the benefit of continuing crizotinib therapy in Chinese patients with progressive ALK-positive NSCLC. Patients with a longer PFS1 and those who received local brain therapy had better survival with continued crizotinib therapy.